The Indian Council of Medical Research has tied up with two biotech companies – Panacea and Serum Institute of India – to conduct a phase III trial of their dengue vaccines. Panacea is likely to start the third phase trial by August or September.
The phase-3 trial for a dengue vaccine developed by Panacea Biotech is likely to begin in a few months, a senior official said as quoted by news agency ANI.
The ICMR, the country’s apex agency for formulation, coordination and promotion of biomedical research, has tied up with two biotech companies Panacea and Serum Institute of India (SII) to conduct phase-III trials of their dengue vaccines.
The phase-3 trial of a dengue vaccine developed by Panacea Biotech in collaboration with the Indian Council of Medical Research (ICMR) is likely to begin in August or September, a senior official said on Tuesday.